Study Comparing 80 mg of Adalimumab With Placebo, and Demonstrating the Non-inferiority of Monthly 80 mg Adalimumab Dosing Compared With 40 mg Adalimumab Every Other Week Dosing

NCT00647270 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

420

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

DRUG: adalimumab
DRUG: Placebo
DRUG: adalimumab

Sponsor

Abbott